• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

慢性中心性浆液性脉络膜视网膜病变光动力治疗后的视网膜解剖学变化

Anatomical Retinal Changes after Photodynamic Therapy in Chronic Central Serous Chorioretinopathy.

作者信息

Ruiz-Del-Tiempo María Pilar, Calvo Pilar, Ferreras Antonio, Leciñena Jesús, Pablo Luis, Ruiz-Moreno Oscar

机构信息

Department of Ophthalmology, Gregorio Marañón University General Hospital, Madrid, Spain.

IIS-Aragón, Department of Ophthalmology, Miguel Servet University Hospital, Zaragoza, Spain.

出版信息

J Ophthalmol. 2018 Feb 6;2018:4081874. doi: 10.1155/2018/4081874. eCollection 2018.

DOI:10.1155/2018/4081874
PMID:29545952
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5818899/
Abstract

PURPOSE

To evaluate anatomical retinal changes measured by spectral-domain optical coherence tomography (SD-OCT), after applying photodynamic therapy (PDT) for treatment of chronic central serous chorioretinopathy (CSC).

METHODS

A retrospective analysis was conducted on 43 patients (48 eyes) with chronic CSC treated with PDT. Visual acuity (VA), central retinal thickness (CRT), outer nuclear layer (ONL) thickness, subretinal fluid (SRF), and photoreceptor ellipsoid zone (EZ) measured by SD-OCT were collected at baseline and at 3, 6, and 12 months after PDT. Differences between normally distributed variables were calculated by a paired-sample -test; < 0.05 was considered statistically significant.

RESULTS

Mean age was 50 ± 9.8 years. Mean time from diagnosis to PDT was 12.5 months. Baseline VA was 0.51 ± 0.24 and significantly improved ( < 0.001) to 0.74 ± 0.26 one year after PDT. CRT and SRF significantly decreased ( < 0.001) at 3, 6, and 12 months after treatment. ONL thickness and EZ did not significantly change at any point during follow-up.

CONCLUSIONS

Not significant changes were found in the ONL or EZ 12 months after PDT.

摘要

目的

评估采用光动力疗法(PDT)治疗慢性中心性浆液性脉络膜视网膜病变(CSC)后,通过光谱域光学相干断层扫描(SD-OCT)测量的视网膜解剖学变化。

方法

对43例(48只眼)接受PDT治疗的慢性CSC患者进行回顾性分析。在基线以及PDT治疗后3、6和12个月时,收集通过SD-OCT测量的视力(VA)、中心视网膜厚度(CRT)、外核层(ONL)厚度、视网膜下液(SRF)和光感受器椭圆体带(EZ)。通过配对样本t检验计算正态分布变量之间的差异;P<0.05被认为具有统计学意义。

结果

平均年龄为50±9.8岁。从诊断到PDT的平均时间为12.5个月。基线视力为0.51±0.24,PDT治疗一年后显著改善(P<0.001)至0.74±0.26。治疗后3、6和12个月时,CRT和SRF显著降低(P<0.001)。随访期间任何时间点ONL厚度和EZ均无显著变化。

结论

PDT治疗12个月后,ONL或EZ未发现显著变化。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bc28/5818899/76c1b73c4ce4/JOPH2018-4081874.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bc28/5818899/76c1b73c4ce4/JOPH2018-4081874.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bc28/5818899/76c1b73c4ce4/JOPH2018-4081874.001.jpg

相似文献

1
Anatomical Retinal Changes after Photodynamic Therapy in Chronic Central Serous Chorioretinopathy.慢性中心性浆液性脉络膜视网膜病变光动力治疗后的视网膜解剖学变化
J Ophthalmol. 2018 Feb 6;2018:4081874. doi: 10.1155/2018/4081874. eCollection 2018.
2
Half-Fluence Photodynamic Therapy for Chronic Central Serous Chorioretinopathy: Predisposing Factors for Visual Acuity Outcomes.半剂量光动力疗法治疗慢性中心性浆液性脉络膜视网膜病变:视力预后的易感因素
Semin Ophthalmol. 2018;33(5):690-699. doi: 10.1080/08820538.2017.1416414. Epub 2017 Dec 18.
3
Correlation between redefined optical coherence tomography parameters and best-corrected visual acuity in non-resolving central serous chorioretinopathy treated with half-dose photodynamic therapy.半剂量光动力疗法治疗未消退中心性浆液性脉络膜视网膜病变中重新定义的光学相干断层扫描参数与最佳矫正视力的相关性。
PLoS One. 2018 Aug 24;13(8):e0202549. doi: 10.1371/journal.pone.0202549. eCollection 2018.
4
Long term outer retinal changes in central serous chorioretinopathy submitted to half-dose photodynamic therapy.中浆患者接受半剂量光动力疗法后的长期外层视网膜改变。
Photodiagnosis Photodyn Ther. 2021 Jun;34:102235. doi: 10.1016/j.pdpdt.2021.102235. Epub 2021 Feb 22.
5
[Observation on long-term efficacy of half-dose photodynamic therapy with chronic central serous chorioretinopathy using optical coherence tomography].[应用光学相干断层扫描观察半剂量光动力疗法治疗慢性中心性浆液性脉络膜视网膜病变的长期疗效]
Zhonghua Yan Ke Za Zhi. 2016 May;52(5):328-34. doi: 10.3760/cma.j.issn.0412-4081.2016.05.004.
6
Microstructural changes after half-dose photodynamic therapy in patients with chronic central serous chorioretinopathy.慢性中心性浆液性脉络膜视网膜病变患者半剂量光动力疗法后的微观结构变化。
Photodiagnosis Photodyn Ther. 2021 Sep;35:102347. doi: 10.1016/j.pdpdt.2021.102347. Epub 2021 May 24.
7
Comparison of the efficacy and safety between subthreshold micropulse laser, standard-fluence and low-fluence photodynamic therapy for chronic central serous chorioretinopathy.亚阈值微脉冲激光、标准强度和低强度光动力疗法治疗慢性中心性浆液性脉络膜视网膜病变的疗效和安全性比较。
J Fr Ophtalmol. 2021 Apr;44(4):499-508. doi: 10.1016/j.jfo.2020.08.027. Epub 2021 Feb 26.
8
Comparison of visual and anatomical outcomes of half-fluence and half-dose photodynamic therapy in eyes with chronic central serous chorioretinopathy.慢性中心性浆液性脉络膜视网膜病变患者中半光通量与半剂量光动力疗法的视觉和解剖学结果比较
Graefes Arch Clin Exp Ophthalmol. 2015 Dec;253(12):2063-73. doi: 10.1007/s00417-014-2926-6. Epub 2015 Jan 24.
9
[Photodynamic therapy for treatment of chronic or recurrent central serous chorioretinopathy].[光动力疗法治疗慢性或复发性中心性浆液性脉络膜视网膜病变]
Zhonghua Yan Ke Za Zhi. 2012 Feb;48(2):106-13.
10
The quantitative evaluation of retinal layers after resolution of subretinal fluid in acute central serous chorioretinopathy.急性中心性浆液性脉络膜视网膜病变视网膜下液吸收后视网膜各层的定量评估
Eur J Ophthalmol. 2022 Nov 3:11206721221136989. doi: 10.1177/11206721221136989.

引用本文的文献

1
Crossover to PDT after the unsuccessful micropulse laser treatment of central serous chorioretinopathy.中心性浆液性脉络膜视网膜病变微脉冲激光治疗失败后交叉接受光动力疗法。
Adv Ophthalmol Pract Res. 2024 Jan 23;4(1):32-38. doi: 10.1016/j.aopr.2024.01.004. eCollection 2024 Feb-Mar.
2
Comparison of the fluorescein angiography-guided and indocyanine green angiography-guided photodynamic therapy in the treatment of non-resolving central serous chorioretinopathy.比较荧光素血管造影引导和吲哚菁绿血管造影引导光动力疗法治疗非缓解性中心性浆液性脉络膜视网膜病变。
Sci Rep. 2023 Jan 30;13(1):1682. doi: 10.1038/s41598-023-28890-9.
3

本文引用的文献

1
Changes of outer retinal microstructures after photodynamic therapy for chronic central serous chorioretinopathy.慢性中心性浆液性脉络膜视网膜病变光动力治疗后视网膜外层微观结构的变化
Clin Ophthalmol. 2017 Aug 16;11:1505-1512. doi: 10.2147/OPTH.S139288. eCollection 2017.
2
One-year outcomes with half-dose verteporfin photodynamic therapy for chronic central serous chorioretinopathy.慢性中心性浆液性脉络膜视网膜病变半剂量维替泊芬光动力疗法治疗一年的结果。
Ophthalmology. 2015 Mar;122(3):555-61. doi: 10.1016/j.ophtha.2014.09.034. Epub 2014 Nov 18.
3
Long-term chorioretinal changes after photodynamic therapy for chronic central serous chorioretinopathy.
Photodynamic Therapy with Verteporfin for Chronic Central Serous Chorioretinopathy: A Review of Data and Efficacy.
维替泊芬光动力疗法治疗慢性中心性浆液性脉络膜视网膜病变:数据与疗效综述
Pharmaceuticals (Basel). 2020 Oct 29;13(11):349. doi: 10.3390/ph13110349.
4
Impairment of visual acuity and retinal morphology following resolved chronic central serous chorioretinopathy.慢性中心性浆液性脉络膜视网膜病变消退后的视力和视网膜形态损害
BMC Ophthalmol. 2019 Jul 25;19(1):160. doi: 10.1186/s12886-019-1171-5.
5
Non-resolving, recurrent and chronic central serous chorioretinopathy: available treatment options.非消退性、复发性和慢性中心性浆液性脉络膜视网膜病变:现有治疗选择。
Eye (Lond). 2019 Jul;33(7):1035-1043. doi: 10.1038/s41433-019-0381-7. Epub 2019 Mar 1.
6
Management of chronic central serous chorioretinopathy.慢性中心性浆液性脉络膜视网膜病变的管理。
Indian J Ophthalmol. 2018 Dec;66(12):1704-1714. doi: 10.4103/ijo.IJO_1077_18.
7
Mineralocorticoid Receptor Antagonist Treatment for Steroid-Induced Central Serous Chorioretinopathy Patients with Continuous Systemic Steroid Treatment.在持续全身使用类固醇治疗的情况下,盐皮质激素受体拮抗剂对类固醇诱导的中心性浆液性脉络膜视网膜病变患者的治疗
J Ophthalmol. 2018 Jul 22;2018:4258763. doi: 10.1155/2018/4258763. eCollection 2018.
慢性中心性浆液性脉络膜视网膜病变光动力疗法后的长期脉络膜视网膜改变。
Graefes Arch Clin Exp Ophthalmol. 2013 Jul;251(7):1697-705. doi: 10.1007/s00417-013-2270-2. Epub 2013 Feb 7.
4
Photodynamic therapy for chronic central serous chorioretinopathy: a 4-year follow-up study.光动力疗法治疗慢性中心性浆液性脉络膜视网膜病变:4 年随访研究。
Retina. 2013 Feb;33(2):309-15. doi: 10.1097/IAE.0b013e3182670fbe.
5
Central serous chorioretinopathy: a review of epidemiology and pathophysiology.中心性浆液性脉络膜视网膜病变:流行病学和发病机制的综述。
Clin Exp Ophthalmol. 2013 Mar;41(2):201-14. doi: 10.1111/j.1442-9071.2012.02848.x. Epub 2012 Sep 21.
6
Review and update of central serous chorioretinopathy.中心性浆液性脉络膜视网膜病变的复习与更新。
Curr Opin Ophthalmol. 2011 May;22(3):166-73. doi: 10.1097/ICU.0b013e3283459826.
7
Comparison of efficacy and safety between half-fluence and full-fluence photodynamic therapy for chronic central serous chorioretinopathy.半剂量与全剂量光动力疗法治疗慢性中心性浆液性脉络膜视网膜病变的疗效和安全性比较。
Retina. 2011 Jan;31(1):119-26. doi: 10.1097/IAE.0b013e3181e378f2.
8
Fluorescein angiography-guided photodynamic therapy with half-dose verteporfin for chronic central serous chorioretinopathy.荧光素血管造影引导的低剂量维替泊芬光动力疗法治疗慢性中心性浆液性脉络膜视网膜病变。
Retina. 2010 Nov-Dec;30(10):1698-703. doi: 10.1097/IAE.0b013e3181da4354.
9
Photodynamic therapy for chronic central serous chorioretinopathy.光动力疗法治疗慢性中心性浆液性脉络膜视网膜病变。
Acta Ophthalmol. 2010 May;88(3):371-6. doi: 10.1111/j.1755-3768.2008.01408.x. Epub 2009 Nov 27.
10
Standard-fluence versus low-fluence photodynamic therapy in chronic central serous chorioretinopathy: a nonrandomized clinical trial.标准强度与低强度光动力疗法治疗慢性中心性浆液性脉络膜视网膜病变的非随机临床试验。
Am J Ophthalmol. 2010 Feb;149(2):307-315.e2. doi: 10.1016/j.ajo.2009.08.026. Epub 2009 Nov 6.